Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#16403
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The companyโs lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$7.02
Last synced: 2026-11-09
Market Cap
$212.39M
Change (1 day)
-6.77%
Change (1 year)
-3.84%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Operating Margin for Cartesian Therapeutics, Inc. (RNAC)
Operating Margin as of November 2026 TTM: -6,679.69%
According to Cartesian Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -6,679.69%. At the end of 2025 the company had an operating margin of -3,099.93%.
Operating Margin history for Cartesian Therapeutics, Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -6,679.69% | 115.48% |
| 2025 | -3,099.93% | 2,647.92% |
| 2024 | -112.81% | -66.05% |
| 2023 | -332.32% | -2,632.93% |
| 2022 | 13.12% | -342.96% |
| 2021 | -5.40% | -98.42% |
| 2020 | -342.36% | -56.42% |
| 2019 | -785.61% | -89.09% |
| 2018 | -7,200.66% | -76.63% |
| 2017 | -30,813.53% | 7,083.98% |
| 2016 | -428.92% | 1.89% |
| 2015 | -420.96% | -16.90% |
| 2014 | -506.55% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.98% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cartesian Therapeutics, Inc.'s operating margin
What is Cartesian Therapeutics, Inc.'s operating margin?
Cartesian Therapeutics, Inc.'s operating margin is -6,679.69%, as of Nov 2026.
What was Cartesian Therapeutics, Inc.'s operating margin in 2025?
In 2025, Cartesian Therapeutics, Inc.'s operating margin was -3,099.93%, compared with -112.81% in 2024.
How has Cartesian Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Cartesian Therapeutics, Inc.'s operating margin was highest in 2022 (13.12%) and lowest in 2025 (-3,099.93%).
How does Cartesian Therapeutics, Inc.'s operating margin compare with similar companies?
Cartesian Therapeutics, Inc.'s operating margin (-6,679.69%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.